Investigation Report on China's Palbociclib Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1006921|
|出版日期||內容資訊||英文 50 Pages
|中國的Palbociclib市場分析(2021年∼2025年) Investigation Report on China's Palbociclib Market 2021-2025|
|出版日期: 2021年05月21日||內容資訊: 英文 50 Pages||
Palbociclib is the world's first selective inhibitor of CDK 4/6 launched by Pfizer. By inhibiting CDK 4/6, Palbociclib restores cell cycle control, thereby blocking tumor cell proliferation. Palbociclib is mainly used to treat advanced breast cancer. In 2018, Pfizer's Palbociclib, IBRANCE entered the Chinese market. By 2020, Pfizer Europe MA EEIG is the only manufacturer in the Chinese Palbociclib market.
According to CRI's market research, after Palbociclib went on the market in China, the sales increased rapidly from CNY298,630 in 2018 to CNY 22.01million in 2019. In 2020, the sales revenue was CNY13.18 million, which decreased 40.12% compared to that in 2019. The main reason is that the COVID-19 epidemic has impacted the overall hospitals' operation. The CAGR of Palbociclib from 2018 to 2020 is 564.36%.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Palbociclib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase as the market expands. At the end of 2020, Pfizer applied for a new indication for Palbociclib in China. If the new indication is approved, the sales of Palbociclib will increase in the following years. On the other hand, Pfizer announced at the beginning of 2021 that it would reduce the price for Palbociclib by about 54%. Therefore, sales volume in 2021 is expected to increase, which will lead to revenue growth. At the same time, with the emergence of new CDK4/6 inhibitors and generic drugs in the Chinese market, the price of Palbociclib may continue to fall. The price reduction will make Palbociclib more affordable for patients, thus further opening up the market.